Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to assess the therapeutic activity of Bevacizumab in combination with Lomustine and of Bevacizumab given as single agent in patients with recurrent GBM who failed combined chemo-irradiation with temozolomide. The primary end-point will be 6 months PFS.
Critère d'inclusion
- Patients with recurrent glioblastoma multiforme who failed combined chemo-irradiation with temozolomide